DAA Types

DAA Types

Current hepatitis C treatments are combinations of drugs called direct-acting antivirals (DAAs). DAAs directly target the hep C virus in different ways to stop it from reproducing. They do this so well that they promise bright futures for those living with hepatitis C and treatments with short treatment times, high cure rates, and few side effects.

There are four classes of direct-acting antivirals that combine in different ways to make up the different hep C DAA treatments. For example, sofosbuvir and velpatasvir combine to make Epclusa.

DAA Types

DAAsVery Roughly What the DAAs DoDAAs Covered by BC PharmaCare (Targeted Genotypes in brackets)
NS3/4A Protease Inhibitors (PIs)NS3/4A protease inhibitors work by blocking a viral enzyme (protease) that enables the hep C virus to survive and replicate in host cells.Glecaprevir (1-6)
Voxilaprevir (1-6)
Grazoprevir (1, 4)
Nucleoside and Nucleotide NS5B Polymerase InhibitorsThey directly target the hep C virus to stop it from making copies of itself in the liver. They attach themselves onto the genetic information, called RNA, to block the virus from multiplying.Sofosbuvir (1-6)
NS5A InhibitorsThey block a virus protein, NS5A, that hep C needs to reproduce and for various stages of infection.Pibrentasvir (1-6)
Elbasvir (1, 4)
Ledipasvir(1)
Velpatasvir (1-6)
Non-Nucleoside NS5B Polymerase InhibitorsThey work to stop hep C from reproducing by inserting themselves into the virus so that other pieces of the hep C virus cannot attach to it.